Evidence map›Paper›PMID 40271157›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

A newly identified pathology of episodic angioedema with hypereosinophilia (Gleich syndrome) revealed by nultiomics analysis.

Tatsuya Koreeda, Hirokazu Muraoka, Yasunori Sato

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tatsuya KoreedaIkawadani-cho, Kobe-shi, Hyogo, Japan.
Hirokazu MuraokaCLINIC FOR Tamachi, Shibaura, Minato-ku, Tokyo, Japan.
Yasunori SatoDepartment of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Episodic angioedema with eosinophilia (Gleich syndrome) is a rare disease marked by periodic angioedema, fever, and severe eosinophilia, with limited understanding of its pathogenesis. Objective: We sought to identify pathogenic factors contributing to severe Gleich syndrome through a comprehensive multiomics approach, using whole-genome sequencing (WGS) and RNA sequencing (RNA-seq). Methods: A multiomics analysis was conducted on a 16- to 20-year-old female patient with severe Gleich syndrome, presenting with periodic high fever, extensive urticaria/eczema, and marked eosinophilia. The analysis included WGS and RNA-seq of blood samples. Results: WGS revealed high-impact pathogenic mutations that have the potential to significantly alter gene function in 16 genes, including PR domain containing 16 (gene involved in transcriptional regulation). RNA-seq identified differentially expressed genes linked to immune response regulation and viral defense. Combined Conclusions: The findings suggest that decreased angiotensin-converting enzyme expression, driven by PR domain containing 16 (gene involved in transcriptional regulation) mutations and altered IFNG expression, may contribute to increased bradykinin levels and activation of the arachidonic acid cascade, leading to the severe inflammation and angioedema characteristic of Gleich syndrome. This study underscores the utility of integrating WGS and RNA-seq data in elucidating the molecular basis of rare diseases and offers a foundation for developing therapeutic strategies for hypereosinophilic syndromes.

Indexed as

Eosinophiliaepisodic angioedema with eosinophiliaGleich syndromehypereosinophilic syndromemultiomics analysisRNA sequencingwhole-genome sequencing

Identifiers

PMID40271157
PMCPMC12013126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.